Ultragenyx Pharmaceutical Inc.
RARE
Rank in Stocks
#6707
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to... Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
Share Price
$16.41
Last synced: 2026-11-09
Market Cap
$1.62B
Change (1 day)
6.35%
Change (1 year)
-51.06%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Ultragenyx Pharmaceutical Inc. (RARE)
Category
Healthcare
Operating Margin for Ultragenyx Pharmaceutical Inc. (RARE)
Operating Margin as of November 2026 TTM: -73.77%
According to Ultragenyx Pharmaceutical Inc.'s latest financial reports, its current operating margin (TTM) is -73.77%. At the end of 2025 the company had an operating margin of -79.49%.
Operating Margin history for Ultragenyx Pharmaceutical Inc. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -73.77% | -7.20% |
| 2025 | -79.49% | -16.91% |
| 2024 | -95.67% | -27.01% |
| 2023 | -131.08% | -26.61% |
| 2022 | -178.60% | 64.41% |
| 2021 | -108.63% | -10.81% |
| 2020 | -121.80% | -70.22% |
| 2019 | -408.98% | -43.29% |
| 2018 | -721.18% | -94.27% |
| 2017 | -12,593.49% | -93.25% |
| 2016 | -186,471.43% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.52% |
US
|
|
| -149.01% | -97.98% |
US
|
|
| 25.57% | -100.35% |
AU
|
|
| 31.23% | -100.42% |
BE
|
|
| 29.35% | -100.40% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Ultragenyx Pharmaceutical Inc.'s operating margin
What is Ultragenyx Pharmaceutical Inc.'s operating margin?
Ultragenyx Pharmaceutical Inc.'s operating margin is -73.77%, as of Nov 2026.
What was Ultragenyx Pharmaceutical Inc.'s operating margin in 2025?
In 2025, Ultragenyx Pharmaceutical Inc.'s operating margin was -79.49%, compared with -95.67% in 2024.
How has Ultragenyx Pharmaceutical Inc.'s operating margin changed since 2020?
From 2020 to 2025, Ultragenyx Pharmaceutical Inc.'s operating margin was highest in 2025 (-79.49%) and lowest in 2022 (-178.60%).
How does Ultragenyx Pharmaceutical Inc.'s operating margin compare with similar companies?
Ultragenyx Pharmaceutical Inc.'s operating margin (-73.77%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.